Forte Biosciences, Inc.
FBRX
Forte Biosciences, Inc. and its subsidiaries (www.fortebiorx.com) ( Forte , we , our ) is a clinical-stage biopharmaceutical company whose current lead product candidate is FB102. FB102 is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$88M
▼ -95.5% YoY
Op. Margin
–
ROIC
-76.66%
▼ -32.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$72M
▼ -65.7% YoY
Op. Cash Flow (TTM)
-$72M
▼ -65.5% YoY
Net Debt
-$198M
Net Cash Position
Cash & Equiv.
$198M
3Y CAGR: -9.8%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with FBRX
Held by ETFs
FBRX is in 4 US ETFs. The largest of them, with FBRX's weight in each:
Forte Biosciences (FBRX) in three numbers
Questions about Forte Biosciences
Is Forte Biosciences a high-quality business?
Forte Biosciences scores 25 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is margin trend at +53384.6pp, and its weakest is return on capital at -76.7%. The Quality tab shows every check against its target.
Does Forte Biosciences (FBRX) pay a dividend?
No. Forte Biosciences (FBRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 7 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 28 Aug 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in FBRX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing FBRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.